Ganolactone B

CAS No. 1028449-53-7

Ganolactone B( —— )

Catalog No. M31412 CAS No. 1028449-53-7

Ganolactone B is a natural product from Ganoderma lucidum.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 261 In Stock
50MG Get Quote In Stock
100MG Get Quote In Stock

Biological Information

  • Product Name
    Ganolactone B
  • Note
    Research use only, not for human use.
  • Brief Description
    Ganolactone B is a natural product from Ganoderma lucidum.
  • Description
    Ganolactone B is a natural product from Ganoderma lucidum.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1028449-53-7
  • Formula Weight
    458.6
  • Molecular Formula
    C27H38O6
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • 3,5-Dimethoxytoluene

    3,5-Dimethoxytoluene (Orcinol dimethyl ether), the main fragrance component in roses, has a sedative effect and can be used as a pest attractant.

  • Hepcidin-1 (mouse) t...

    Hepcidin-1 (mouse) is an endogenous peptide hormone involved in the regulation of iron homeostasis. Hepcidin-1 (mouse) upregulates mRNA levels of TRAP, cathepsin K, and MMP-9 and increases TRAP-5b protein secretion. Hepcidin-1 (mouse) downregulates the level of FPN1 protein and increases intracellular iron. Hepcidin-1 (mouse) facilitates osteoclast differentiation.

  • MAGE-A3 195-203

    This peptide MAGE-3-encoded HLA-A24 epitope is a high MHC binder.The identification of this MAGE-3/HLA-A24 peptide may as a result effectiveially offer the opportunities to design peptide-based immunotherapeutic approaches that might prove to be potent in treating patients with MAGE-3-positive malignant tumors.